Trial Profile
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 6 to 35 Months
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A; AS03B
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 24 Nov 2010 Status changed from active, no longer recruiting to completed, according the the GlaxoSmithKline website.
- 28 Jun 2010 Primary endpoint `meeting or exceeding the humoral immune response criteria of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)' has been met.
- 28 Jun 2010 Results reported in Vaccine.